Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Oxycodone 40mg/5ml / Naloxone 20mg/5ml oral suspension
0407020AFAAAEAE
|
Oxycodone hydrochloride/naloxone hydrochloride | Oxycodone hydrochloride/naloxone hydrochloride | Central Nervous System | No data available |
|
Oxycodone hydrochloride 60mg suppositories
0407020Z0AAABAB
|
Oxycodone | Oxycodone | Central Nervous System | No data available |
|
Oxylan 10mg modified-release tablets (Actavis)
0407020ADBFAGAF
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 20mg modified-release tablets (Actavis)
0407020ADBFAHAG
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 40mg modified-release tablets (Actavis)
0407020ADBFAIAH
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 5mg modified-release tablets (Actavis)
0407020ADBFAFAK
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 80mg modified-release tablets (Actavis)
0407020ADBFAJAI
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxymetholone 25mg/5ml oral suspension
0901030H0AAAEAE
|
Oxymetholone | Oxymetholone | Nutrition and Blood | No data available |
|
Oxymetholone 50mg capsules
0901030H0AAAFAF
|
Oxymetholone | Oxymetholone | Nutrition and Blood | No data available |
|
Oxymetholone 50mg tablets
0901030H0AAAGAG
|
Oxymetholone | Oxymetholone | Nutrition and Blood | No data available |
|
Oxymycin 250mg tablets
0501030T0BFAAAJ
|
Oxymycin | Oxytetracycline | Infections | No data available |
|
Oxypertine 10mg capsules
0402010N0AAAAAA
|
Oxypertine | Oxypertine | Central Nervous System | No data available |
|
Oxypertine 40mg tablets
0402010N0AAABAB
|
Oxypertine | Oxypertine | Central Nervous System | No data available |
|
Oxytetracycline 100mg/5ml oral suspension
0501030T0AAATAT
|
Oxytetracycline (Systemic) | Oxytetracycline | Infections | No data available |
|
Oxytetracycline 125mg/5ml oral suspension
0501030T0AAAPAP
|
Oxytetracycline (Systemic) | Oxytetracycline | Infections | No data available |
|
Oxytetracycline 250mg/5ml oral suspension
0501030T0AAAQAQ
|
Oxytetracycline (Systemic) | Oxytetracycline | Infections | No data available |
|
Oxytetracycline 500mg/5ml oral suspension
0501030T0AAARAR
|
Oxytetracycline (Systemic) | Oxytetracycline | Infections | No data available |
|
Oxytetramix 250 tablets
0501030T0BIAAAJ
|
Oxytetramix-250 | Oxytetracycline | Infections | No data available |
|
Oxytocin 10units/1ml solution for injection ampoules
0701010T0AAACAC
|
Oxytocin | Oxytocin | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Oxytocin 5units/1ml solution for injection ampoules
0701010T0AAABAB
|
Oxytocin | Oxytocin | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Oxyzyme dressing 10cm x 10cm square
20031700050
|
Oxyzyme dressing 10cm x 10cm square | Wound Management & Other Dressings | Dressings | No data available |
|
Oxyzyme dressing 6.5cm x 5cm rectangular
20031700051
|
Oxyzyme dressing 6.5cm x 5cm rectangular | Wound Management & Other Dressings | Dressings | No data available |
|
Oyavas 100mg/4ml concentrate for solution for infusion vials
0801050APBFABAA
|
Oyavas | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Oyavas 400mg/16ml concentrate for inf vials
0801050APBFAAAB
|
Oyavas | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Ozanimod 230microgram caps and Ozanimod 460microgram caps
0802040BFAAABAB
|
Ozanimod | Ozanimod | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.